These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Multiple effects of Honokiol on the life cycle of hepatitis C virus. Lan KH; Wang YW; Lee WP; Lan KL; Tseng SH; Hung LR; Yen SH; Lin HC; Lee SD Liver Int; 2012 Jul; 32(6):989-97. PubMed ID: 22098176 [TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus genetic variability in patients undergoing antiviral therapy. Cristina J; del Pilar Moreno M; Moratorio G Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128 [TBL] [Abstract][Full Text] [Related]
25. A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the hepatitis C virus. Fukazawa H; Suzuki T; Wakita T; Murakami Y Biol Pharm Bull; 2012; 35(8):1320-7. PubMed ID: 22863932 [TBL] [Abstract][Full Text] [Related]
26. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS]. Gozlan Y; Mendelson E; Ben-Ari Z; Mor O Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497 [TBL] [Abstract][Full Text] [Related]
27. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546 [TBL] [Abstract][Full Text] [Related]
28. Caffeine inhibits hepatitis C virus replication in vitro. Batista MN; Carneiro BM; Braga AC; Rahal P Arch Virol; 2015 Feb; 160(2):399-407. PubMed ID: 25491197 [TBL] [Abstract][Full Text] [Related]
29. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911 [TBL] [Abstract][Full Text] [Related]
30. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Ciesek S; von Hahn T; Colpitts CC; Schang LM; Friesland M; Steinmann J; Manns MP; Ott M; Wedemeyer H; Meuleman P; Pietschmann T; Steinmann E Hepatology; 2011 Dec; 54(6):1947-55. PubMed ID: 21837753 [TBL] [Abstract][Full Text] [Related]
31. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. Wagoner J; Morishima C; Graf TN; Oberlies NH; Teissier E; Pécheur EI; Tavis JE; Polyak SJ PLoS One; 2011 Jan; 6(1):e16464. PubMed ID: 21297992 [TBL] [Abstract][Full Text] [Related]
32. New hepatitis C therapies: the toolbox, strategies, and challenges. Pawlotsky JM Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495 [TBL] [Abstract][Full Text] [Related]
33. Are statins a viable option for the treatment of infections with the hepatitis C virus? Verpaalen B; Neyts J; Delang L Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180 [TBL] [Abstract][Full Text] [Related]
34. [Subgenomic replications of hepatitis C virus (HCV): new possibilities for hepatitis C prophylaxis and treatment]. Puig-Basagoiti F; Sáiz JC Gastroenterol Hepatol; 2001 Dec; 24(10):506-10. PubMed ID: 11730621 [No Abstract] [Full Text] [Related]
35. Plant-derived antivirals against hepatitis c virus infection. Jardim ACG; Shimizu JF; Rahal P; Harris M Virol J; 2018 Feb; 15(1):34. PubMed ID: 29439720 [TBL] [Abstract][Full Text] [Related]
36. The safety of daclatasvir for the treatment of hepatitis C. Jafri SM; Gordon SC Expert Opin Drug Saf; 2015; 14(11):1787-97. PubMed ID: 26571362 [TBL] [Abstract][Full Text] [Related]